Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orca-T and CD19/CD22-CAR T Cells in B-Cell ALL
NCT05507827Phase 1Active, not recruiting
- Start
- Aug 2022
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19/CD22-CAR T cells in acute lymphoblastic leukemia (ALL). Primary endpoints: Number of Patients Who Received Donor CD19/CD22-CAR T Cells at 42 days and Assessment of the Donors Safety CD19/CD22-CAR T Cells Plus the Orca-T Graft at 42 days. Started Aug 2022; status: active, not recruiting.
02
Drugs
CD19/CD22-CAR T cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05507827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507827.